All the Active Ingredient Drugs
Acetylcholinesterase Inhibitor. Rivastigmine 1.5, 3, 4.5 , 6 mg. CAPS: 28 x 1.5, 3, 4.5.
Initi. dose: 1.5 mg ×2/d., Pts. known to
be particul. sensit. to the effects of cholinerg. drugs should be start. at a dose of 1 mg ×2/d. Dose titrat. Init.: 1.5 mg×2/d. If this dose is well toler. after a minim. of 2 wks. of tmt., the dose may be incr. to 3 mg×2/d. Subseq. incr. to 4.5 mg and then 6 mg ×2/d based on good tolerab. of the current dose and may
be consid. after a minim. of 2 wks. tmt.
at that dose level.
If adverse effects (e.g. naus., vomit.,
abd. pain, loss of appetite) wt. decr. are
observ. during tmt., these may
respond to omit. one or more doses. If
ADR effects persist, the dly. dose
should be reduced to the previous
well-tolerat. dose.
Re-init. of therapy: If tmt. is interrupt.
for longer than 3 d, tmt. should be
re-init. with 1.5 mg ×2/d and titrat. as
described above.
Mainten. dose: 1.5 mg -6 mg ×2/d; to
achieve max. therap. benefit pts. should
be maintain. on their highest well tolerated dose.
Recommend. max. dly. dose 6 mg ×2/a
Caps. should be admin. with morn.and even. meals.
Tmt. of pts. with mild – moder. sev. dement.
of the alzheimer type, also termed probable
alzheimer’s dis. or alzheimer’s dis. Symptom. tmt. of mild to moder. sev. alzheimer’s dement. Symptom. tmt. of mild – moder. sev. dementia assoc. with Parkinson’s dis.
C/I: Known hypersens. to rivastigmine,
to other carbamate derivat.
Prev. history of applicat. site react.
suggest. of allerg. contact dermatit. with
rivastigmine transderm. patch.
Acetylcholinesterase Inhibitor. Rivastigmine 4.6, 9.5, 13.3 mg/24 hours. TRANSDERMAL PATCHES: 30 x 9
mg/5cm2 (releases 4.6 mg/24 hrs; 18
mg/10 cm2 (releases 9.5 mg/24 hrs). 1
patch 1 x dly. See lit.
Tmt. mild-moderat. severe dement. of
Alzheimer type.
C/I: Known hypersens. to rivastigmine,
other carbamate derivs.
Acetylcholinesterase Inhibitor. Rivastigmine 1.5, 3, 4.5, 6 mg. CAPS.: 28 x 1.5mg, 3mg, 4.5mg, 6mg
Init. dose 1.5 mg × 2/d. Pts. with sensit. to cholinergics start. with 1 mg × 2/d.
Dose titrat.: After a min. of 2 wks., may be incr. to 3 mg × 2/d. Subseq. incr. to 4.5 mg and then 6 mg × 2/d should also be based on good tolerab. of the current dose and may be consid. after a min. of 2 wks. tmt. at that dose level.
Main. dose: 1.5 mg - 6 mg × 2/d; to achieve max. therap. benefit pts. should be maint. on their highest welltoler.dose. Recomm. max. dly. dose: 6 mg × 2/d.
Tmt. of pts. with mild to moderat. sev. dementia of the Alzheimer type, also termed probable alzheimer's disease or alzheimer's dis.
Symptom. tmt. of mild- moder. sev. alzheimer's dementia.
Symptom. tmt. of mild –moder. sev. dementia assoc. with Parkinson's dis.
C/I: Hypersens. to rivastigmine, to other carbamate derivat.
Previous history of application site react. suggestive of allergic contact dermatitis with
rivastigmine transderm.patch. See lit.
Acetylcholinesterase Inhibitor. Rivastigmine 4.6 mg/24h, 9.5 mg/24h. TRANSDERMAL PATCHES: 30 X 4.6 mg/24h, 9.5 mg/24h.
One patch once a day. See lit.
Tmt. of mild-moder. dementia of the Alzheimer's type.
C/I: Hypersens. Prev. history of application site react. suggestive of allergic contact dermatitis with Rivastigmine transder. patch and. See lit.
